A Kick-Start for CLC Antiporters’ Pharmacology  by Zifarelli, Giovanni & Pusch, Michael
Chemistry & Biology
PreviewA Kick-Start for CLC Antiporters’ PharmacologyGiovanni Zifarelli1 and Michael Pusch1,*
1Istituto di Biofisica, CNR, Via De Marini, 6, I-16149 Genova, Italy
*Correspondence: pusch@ge.ibf.cnr.it
http://dx.doi.org/10.1016/j.chembiol.2012.10.009
Despite the role of chloride channels and anion/proton antiporters of the CLC protein family in physiological
processes and different genetic diseases, their pharmacology has been under-developed. In this issue of
Chemistry & Biology, Howery et al. report the synthesis of 40-octanamidostilbene-2,20-disulfonate, the first
high-affinity inhibitor of a CLC antiporter, a critical step toward reviving the CLC pharmacology.High affinity inhibitors of membrane
transport proteins have not only a high
relevance in pharmacology as lead
compounds for drug development, but
also as valuable molecular probes
to help elucidate membrane transport
mechanisms. In this issue of Chemistry &
Biology, Howery et al. (2012) describe
the synthesis and characterization of
4,40-octanamidostilbene-2,20-disulfonate
(OADS), the first high affinity inhibitor spe-
cific for a CLC antiporter from Escherichia
coli (ClC-ec1).
This achievement might provide a
fundamental pharmacological and bio-
physical tool to investigate the CLC
protein family. In fact, several CLC
proteins are involved in genetic diseases,
attesting their physiological and phar-
macological relevance (Jentsch, 2008).
Moreover, they represent a biophysical
puzzle because they have so far defied
the classical divide between ion channels
and transporters; in this protein family,
passive ion diffusion, such as that seen
in CLC-channels like the muscle channel
ClC-1, and coupled thermodynamically
uphill transport (for example in CLC Cl/
H+ antiporters like the bacterial ClC-ec1)
are carried out using the same molecular
architecture (Accardi and Miller, 2004;
Zifarelli and Pusch, 2007). Therefore,
specific CLC inhibitors would be impor-
tant tools to examine several aspects of
CLC function. Unfortunately, the majority
of small molecule modulators that have
been identified so far (like flufenamic
acid, niflumic acid, clofibric acid deriva-
tives, and 9-anthracene carboxylate) are
unspecific and have relatively low affinity
with promising results obtained only for
ClC-Ka (Gradogna and Pusch, 2010).
Previous mutagenesis studies have iden-
tified residues that are likely involved in
the binding sites of intracellular blockers1358 Chemistry & Biology 19, November 21,of ClC-0 and ClC-1 (Este´vez et al., 2003)
and extracellular blockers of CLC-K
channels (Picollo et al., 2004), consistent
with the idea that these blockers bind in
the pore region of the channels. However,
none of these compounds are effective on
the mammalian CLC Cl/H+ antiporters
and the prokaryotic CLC homologs that
are amenable to structural and bio-
chemical analysis, thus precluding the
possibility of a rational chemical modi-
fication that might improve their proper-
ties. The discovery that OADS inhibits
ClC-ec1 at low-micromolar concen-
trations is therefore a potential ‘‘turning
point’’, which, as other aspects of CLC
history, was borne out of fortuitous
circumstances.
In fact, OADS’ design is a combina-
tion of elements present in other known
CLC inhibitors. However, their assembly
in a new molecule confers distinctly
new inhibitory properties. OADS com-
bines 4,40-diaminostilbene-2,20-disulfo-
nate (DADS; Matulef et al., 2008) with
the two aliphatic side chains present in
octanoic acid (Rychkov et al., 2001).
DADS is closely related to 4,40-diisothio-
cyanatostilbene-2,20-disulfonate (DIDS),
a small molecule that acts on both cation-
and anion-transporting proteins and
inhibits ClC-ec1 with an apparent affinity
of 300 mM besides inhibiting ClC-0 and
ClC-Ka (Matulef et al., 2008). Importantly,
DIDS was shown to inhibit ClC-Ka by
binding inside the channel pore (Picollo
et al., 2004). To make things worse,
DIDS is difficult to work with because
it hydrolyzes easily in water, frustrating
any attempt of structural analysis or
rational chemical modification to improve
its characteristics. However, surprisingly,
DADS reacts with DIDS, forming oligo-
mers that inhibit ClC-ec1, ClC-0, and
ClC-Ka much more potently than DIDS2012 ª2012 Elsevier Ltd All rights reservedbut with the same mechanism (Matulef
et al., 2008). This fortuitous event was a
trigger for testing new DADS-containing
compounds. The other component of
OADS design, octanoic acid, is a hydro-
phobic anion known to inhibit the ClC-0
and ClC-1 channels by binding to the
channel pore (Rychkov et al., 2001; Zhang
et al., 2009).
In summary, the combination of two
‘‘parent’’ compounds that do not have
any effect on the antiporter ClC-ec1
gave rise to a new compound: OADS
that specifically inhibits ClC-ec1 with
high affinity by binding, not to the pore,
but in a more lateral position in the cyto-
plasmic region of the antiporter. In par-
ticular, by a clever combination of
different functional assays, biochemical
techniques, and molecular dynamics
simulations, Howery et al. (2012) were
able to propose that OADS inhibits
ClC-ec1 with a 2:1 stoichiometry, thus
involving two binding sites. These two
binding sites differ in their roles. While
one binding site, formed by R28 and
K216, is responsible for the inhibition,
the other, formed by K169, is not involved
in the inhibition, but is essential to pro-
mote binding to the first site (Figure 1).
Interestingly, based on the crystal struc-
ture of the CmCLC transporter (Feng
et al., 2010), the intracellular CBS (from
cystathionine-beta-synthase) domains
present in eukaryotic CLC proteins do
not seem to interfere with OADS’ binding
sites (Figure 1).
The mechanism of OADS action pres-
ents several interesting aspects that will
trigger further studies. Howery et al.
(2012) provide compelling evidence that
OADS does not act as a classic ‘‘pore
blocker,’’ and that it involves coopera-
tion between two binding sites, but
the detailed molecular mechanism of
Figure 1. Position of the OADS’ Binding Site Mapped on the Crystal Structure of the
Eukaryotic CLC Transporter CmCLC
(A) Side view of the transporter with the two subunits shown in different green (transmembrane part) and
orange (cytoplasmic part) shades. Chloride ions are shown as magenta spheres. The CmCLC residues
corresponding to R28, K169, and K216 of ClC-ec1 (according to the sequence alignment of Feng et al.
[2010]) are respectively S88 (red), T234 (cyan), and W281 (blue) and are shown as spheres.
(B) Expanded representation (tilted view) of the region surrounding the same residues.
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vide important insight into possible con-
formational changes associated with the
transport cycle of CLC antiporters. On
the other hand, the lack of effect of
OADS on ClC-1 might give structural
and functional clues on the difference
between CLC channels and transporters.
The validity of OADS as a starting point
to design drugs able to treat the diseases
caused by dysfunctions of the intra-
cellular eukaryotic transporters ClC-5
and ClC-7 (Dent’s disease and osteopet-
rosis) requires additional test of OADS
efficacy on these proteins. Moreover,
when considering OADS as a potential
drug, it should be kept in mind that the
strong hydrophobicity of the molecule
might result in unspecific effects onmembrane proteins and possibly hinder
its partition to the cytoplasm. The influ-
ence of the lipidic composition of the
membrane (especially cardiolipin) on
OADS potency (Howery et al., 2012)
is another intriguing aspect that will
attract further attention. In particular, the
pronounced effect of cardiolipin on
the turnover rate of ClC-ec1 (Howery
et al., 2012) is, in itself, an interesting
feature that deserves specific scrutiny.
Although, so far, the authors have not
succeed in obtaining a crystal structure
of ClC-ec1 in combination with OADS,
it is reasonable to anticipate that the
possibility to deploy a wide range of
biochemical techniques, allowed by the
effect of OADS on a bacterial protein, will
lay the foundations for relevant progressChemistry & Biology 19, November 21, 2012 ªin the pharmacology of the CLC protein
family.
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